<DOC>
	<DOCNO>NCT00730652</DOCNO>
	<brief_summary>To determine MDX-1411 safe treatment chronic lymphocytic leukemia mantle cell lymphoma .</brief_summary>
	<brief_title>Study MDX-1411 Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Mantle Cell Lymphoma</brief_title>
	<detailed_description>Dose-escalation , multidose study MDX-1411 , fully human nonfucosylated monoclonal antibody ( mAb ) target CD70 transmembrane cell-surface protein , highly express B-cell malignancy CLL MCL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<criteria>Histologically confirm diagnosis relapsed/refractory MCL hematologically/bone marrow confirm relapsed/refractory CLL amenable cure surgery mean fail least 1 prior systemic therapy ; Subjects may treat 6 prior systemic therapy relapsed/refractory disease become intolerant systemic therapy For MCL , must measurable disease At least 4 week since last systemic therapy , include RT , treatment MCL/CLL ; At least 4 week since take corticosteroid prior first dose MDX1411 ECOG Performance Status 0 2 ; No know positivity human immunodeficiency virus ( HIV ) active infection Hepatitis B Hepatitis C ; History severe hypersensitivity reaction monoclonal antibody ; Use investigational drug within 30 day study drug administration Prior treatment antiCD70 antibody ; Active infection require i.v . systemic therapy within 4 week receive first dose MDX1411 ; Evidence bleed diathesis coagulopathy ; Active autoimmune disease require immunosuppressive therapy ; Known current drug alcohol abuse ; Underlying medical condition make administration MDX1411 hazardous</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Medarex Inc .</keyword>
</DOC>